Temferon
Glioblastoma Multiforme (unmethylated MGMT promoter)
Key Facts
About Genenta Science
Genenta Science's mission is to develop durable, patient-specific gene therapies for solid tumors by engineering hematopoietic stem cells to produce therapeutics directly within the tumor microenvironment. Its lead candidate, Temferon, has progressed through Phase 1/2 clinical trials for glioblastoma multiforme (GBM). In a significant strategic pivot, the company is evolving into Saentra Forge, aiming to build a multi-pillar industrial group through acquisitions in biotechnology and national-security regulated sectors, while continuing to advance its core Temferon platform.
View full company profileAbout Genenta Science
Genenta Science's mission is to develop durable, patient-specific gene therapies for solid tumors by engineering hematopoietic stem cells to produce therapeutics directly within the tumor microenvironment. Its lead candidate, Temferon, has progressed through Phase 1/2 clinical trials for glioblastoma multiforme (GBM). In a significant strategic pivot, the company is evolving into Saentra Forge, aiming to build a multi-pillar industrial group through acquisitions in biotechnology and national-security regulated sectors, while continuing to advance its core Temferon platform.
View full company profileAbout Genenta Science
Genenta Science's mission is to develop durable, patient-specific gene therapies for solid tumors by engineering hematopoietic stem cells to produce therapeutics directly within the tumor microenvironment. Its lead candidate, Temferon, has progressed through Phase 1/2 clinical trials for glioblastoma multiforme (GBM). In a significant strategic pivot, the company is evolving into Saentra Forge, aiming to build a multi-pillar industrial group through acquisitions in biotechnology and national-security regulated sectors, while continuing to advance its core Temferon platform.
View full company profile